Corporate Presentation April 29th, 2025 Forward Looking Statements and Disclaimer The presentation contains forward-looking statements. Statements made or presented may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "believe," "anticipate," "plan," "expect," "intend," "will," "may," "goal," "potential," "should," " ...

Core Viewpoint - Innovent Biologics is set to present multiple clinical study results of mazdutide at the American Diabetes Association's 85th Scientific Sessions, highlighting its potential as a next-generation treatment for Type 2 Diabetes (T2D) and other metabolic diseases [1] Group 1: Clinical Studies and Presentations - The first Phase 3 study of mazdutide in Chinese adults with T2D (DREAMS-1) will be presented orally [1] - Multiple exploratory mechanism of action (MoA) analyses of mazdutide and a preclinical study of IBI3030 will be showcased in poster presentations [1] - The presentations include various studies on mazdutide's effects on liver fat accumulation, hyperuricemia, and cardiovascular risk markers [1][1][1] Group 2: Product Development and Regulatory Status - Mazdutide is currently under review with two New Drug Applications (NDAs) accepted by the National Medical Products Administration (NMPA) [4] - The drug is being evaluated in six Phase 3 clinical studies, with GLORY-1, DREAMS-1, and DREAMS-2 having met their primary endpoints [4] - Innovent has plans for several new clinical studies involving mazdutide, targeting conditions such as metabolic dysfunction-associated steatohepatitis (MASH) and heart failure with preserved ejection fraction (HFpEF) [7] Group 3: Company Overview and Partnerships - Innovent Biologics, founded in 2011, focuses on developing high-quality biopharmaceuticals for various diseases, including oncology and metabolic disorders [4] - The company has launched 15 products and has 3 new drug applications under regulatory review, with 4 assets in Phase III trials and 15 molecules in early clinical stages [4] - Innovent collaborates with over 30 global healthcare companies, including Eli Lilly, to enhance its product offerings and market reach [4]

2025 First Quarter Financial and Corporate Update April 29, 2025 First Quarter 2025 Earnings Call Agenda | Introduction | Greg Shertzer Investor Relations | | --- | --- | | Key Highlights & Commercial | Hervé Hoppenot | | Review | Chief Executive Officer | | Financial Review | Christiana Stamoulis Chief Financial Officer | | R&D Update | Pablo Cagnoni | | | Head of Research & Development | | Closing Remarks | Hervé Hoppenot | | | Chief Executive Officer | | | Matteo Trotta EVP, Head of U.S. Dermatology | | ...